Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. EpiCept Corporation is a specialty pharmaceutical company focused on the development and commercialisation of topically-delivered prescription pain management therapeutics. All of the company's product candidates target moderate-to-severe pain that is influenced, or mediated, by nerve receptors located just beneath the skin's surface. EpiCept's product candidates utilise proprietary formulations and several topical delivery technologies to administer FDA-approved pain management therapeutics, or analgesics directly on the skin's surface at or near the site of the pain.

On 4th January 2006, EpiCept completed a merger with Maxim Pharmaceuticals and began trading on the Nasdaq National Market system the following day. The new company combines a relatively low-risk product portfolio of commercially promising topical pain therapies with the upside potential of a late-stage cancer product and the biopharmaceutical discovery capabilities for apoptosis inducers designed to address unmet medical needs in oncology and other serious conditions. EpiCept is expected to continue to operate Maxim's research facility in San Diego, CA. EpiCept also has operations in Munich, Germany.

EpiCept issued shares of its common stock to Maxim stockholders in exchange for all of the outstanding shares of Maxim. EpiCept's stockholders retained approximately 72 per cent ownership of the combined company and former Maxim stockholders received approximately 28 per cent, calculated on a fully-diluted basis at the closing of the merger. The exchange ratio is 0.203969 of an EpiCept share for each Maxim share. Based on the recent trading price of Maxim's common stock, the transaction would represent an implied equity value of approximately US$136 million for the combined company.